Table 3.
% of lag phase increment
|
% of Rf inhibition
|
|||
---|---|---|---|---|
R | P | R | P | |
Esterified cholesterol (%) | 0.198 | 0.053 | −0,195 | 0.055 |
Free cholesterol (%) | 0.239 | 0.019d | −0.118 | 0.248 |
Triglyceride (%) | 0.152 | 0.140 | 0.154 | 0.133 |
Phospholipid (%) | −0.021 | 0.428 | 0.165 | 0.106 |
NEFA (mol/mol apoA-I) | 0.146 | 0.157 | 0.301 | 0.003d |
apoA-I (%) | −0,201 | 0.050d | −0.126 | 0.220 |
apoA-II (%) | −0.035 | 0.734 | 0.013 | 0.902 |
PON1 (plasma activity) | −0.058 | 0.577 | 0.108 | 0.297 |
PAF-AH (HDL activity) | 0.097 | 0.349 | −0.023 | 0.822 |
Neutral lipids/polar lipidsa | 0.314 | 0.002d | −0.166 | 0.105 |
Core/surfaceb | 0.366 | <0.001d | −0.135 | 0.189 |
Lipid/proteinc | 0.150 | 0.144 | 0.086 | 0.403 |
Ratio triglycerides+esterified cholesterol/phospholipids+free cholesterol;
Ratio triglycerides + esterified cholesterol/phospholipids + free cholesterol+apoA-I+apoA-II;
Ratio triglycerides+cholesterol+phospholipids/apoA-I+apoA-II;
Statistically significant associations.